Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019

On September 23, 2019 Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, reported that it will present several posters highlighting clinical data from three of its ongoing programs for oral paclitaxel and encequidar ("Oral Paclitaxel"; f.k.a Oraxol or oral paclitaxel and HM30181) at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2019 to be held September 27 – October 1, 2019 in Barcelona, Spain (Press release, Athenex, SEP 23, 2019, View Source [SID1234573885]). The posters demonstrate the results from clinical studies of Oral Paclitaxel for patients with a number of advanced solid tumor types as well as in combination with ramucirumab, an anti-VEGFR2 antibody therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Please see the presentation details below. The abstracts can be found within the conference calendar here.

Poster: 477P
Title: An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Session: Poster Display session
Date: September 28, 2019
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Speaker: Edmond Ang (New Zealand)

Poster: 1733TiP
Title: A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Session: Poster Display session
Date: September 28, 2019
Time: 12:00 – 13:00 CEST
Location: Poster Area (Hall 4)
Speaker: Herbert H. Loong (Shatin, Hong Kong PRC)

Poster: 800P
Title: A Phase 1b Study of Oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy
Date: September 29, 2019
Time: 12:00 – 13:00 CEST
Session: Poster Display session
Location: Poster Area (Hall 4)
Speaker: Ming Huang Chen (Taipei City, Taiwan)

The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.